reshape medical is a development-stage medical device manufacturer headquartered in southern california. the company is focused on the development of non-surgical weight loss devices that can be used as aids in the treatment of obese or overweight patients. there are millions of people looking for a solution to assist them in their battle to lose weight, but many are afraid of the risks of surgery. previously, few if any options existed between drugs for weight loss and invasive surgical restructuring of the anatomy. reshape medical intends to broaden the options and is developing less invasive devices for weight loss treatment.
Company profile
Ticker
RSLS
Exchange
Website
CEO
Andrew Rasdal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
OBALON THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
ReShape Weightloss, Inc. • ReShape Lifesciences Netherlands B.V. • ReShape Lifesciences Australia Pty Ltd • ReShape Costa Rica Sociedad de Responsabilidad Limited • Obalon Center for Weight Loss, Inc. ...
RSLS stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Apr 24
8-K
Changes in Registrant's Certifying Accountant
9 Apr 24
8-K
Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX
4 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
26 Feb 24
DEF 14A
Definitive proxy
24 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Jan 24
PRE 14A
Preliminary proxy
5 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
Transcripts
RSLS
Earnings call transcript
2023 Q4
1 Apr 24
RSLS
Earnings call transcript
2023 Q3
8 Nov 23
RSLS
Earnings call transcript
2023 Q2
7 Aug 23
RSLS
Earnings call transcript
2023 Q1
15 May 23
RSLS
Earnings call transcript
2022 Q4
25 Apr 23
RSLS
Earnings call transcript
2022 Q3
14 Nov 22
RSLS
Earnings call transcript
2022 Q2
16 Aug 22
RSLS
Earnings call transcript
2021 Q3
11 Nov 21
RSLS
Earnings call transcript
2021 Q2
16 Aug 21
RSLS
Earnings call transcript
2021 Q1
18 May 21
Latest ownership filings
SC 13G
Schneid Yair
17 Jan 24
3
Yair Schneid
16 Jan 24
4
THOMAS STANKOVICH
8 Nov 23
4
THOMAS STANKOVICH
19 Jul 23
4
THOMAS STANKOVICH
6 Jul 23
SC 13D
Matthew Joseph Nachtrab Revocable Trust 2014
17 Mar 23
4
THOMAS STANKOVICH
7 Mar 23
SC 13D
FOLEY & LARDNER/ FA
15 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
4
THOMAS STANKOVICH
20 Dec 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.55 mm | 1.55 mm | 1.55 mm | 1.55 mm | 1.55 mm | 1.55 mm |
Cash burn (monthly) | 1.04 mm | 391.33 k | 1.29 mm | 2.52 mm | 926.67 k | 1.44 mm |
Cash used (since last report) | 7.13 mm | 2.68 mm | 8.87 mm | 17.24 mm | 6.35 mm | 9.90 mm |
Cash remaining | -5.58 mm | -1.13 mm | -7.32 mm | -15.69 mm | -4.80 mm | -8.35 mm |
Runway (months of cash) | -5.4 | -2.9 | -5.7 | -6.2 | -5.2 | -5.8 |
Institutional ownership, Q2 2023
1.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 0 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 155.14 mm |
Total shares | 440.01 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Foley & LARDNER/ Fa | 133.85 k | $930.00 k |
Matthew Joseph Nachtrab Revocable Trust 2014 | 133.85 k | $930.00 k |
Domain Parters Vii L P | 62.50 k | $0.00 |
Vanguard | 49.87 k | $73.81 mm |
BLK Blackrock | 34.06 k | $50.41 mm |
STT State Street | 13.02 k | $19.26 mm |
Interwest Partners X | 6.25 k | $10.00 k |
UBS UBS Group AG - Registered Shares | 2.89 k | $4.28 mm |
JPM JPMorgan Chase & Co. | 1.86 k | $2.75 mm |
Tower Research Capital | 1.85 k | $2.74 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Oct 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.27 | 131 | 35.37 | 22,949 |
11 Oct 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.93 | 39 | 36.27 | 23,080 |
1 Sep 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 0.89 | 118 | 105.02 | 23,119 |
24 Aug 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 1.42 | 39 | 55.38 | 23,237 |
4 Aug 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 1.43 | 108 | 154.44 | 23,276 |
6 Jul 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 1.47 | 106 | 155.82 | 23,384 |
28 Feb 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 4.25 | 103 | 437.75 | 6,091 |
2 Feb 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 13.29 | 157 | 2.09 k | 6,194 |
24 Jan 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 7.4906 | 110 | 823.97 | 6,351 |
24 Jan 23 | Thomas Stankovich | Common Stock, $0.001 par value per share | Sell | Dispose S | No | No | 7.49 | 48 | 359.52 | 6,461 |
News
ReShape Lifesciences Tweets 'Will #GLP1 medications replace #weightloss #surgery? According to ReShape CEO, Paul Hickey, via @InvestingCom, #GLP1s are a very attractive tool to fight #obesity. However, our ReShape Lap-Band® is safe and less invasive'
3 Apr 24
Reshape Lifesciences FY23 Sales $8.678M Miss $8.904M Estimate
1 Apr 24
ReShape Lifesciences Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 FLEX
22 Feb 24
ReShape Lifesciences Posts On X "There Is Growing Consumer Awareness Of Medical #weightloss Generated By GLP-1s. Reshape Lifesciences Is Tapping Into This Market With Our Full Portfolio Of Weight Loss And Wellness Solutions"
20 Feb 24
Press releases
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
1 Apr 24
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
28 Mar 24
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
4 Mar 24
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
22 Feb 24